Market Overview

Immunogen: Q1 Earnings Insights


Shares of Immunogen (NASDAQ:IMGN) gained 10% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share were up 43.33% over the past year to ($0.17), which missed the estimate of ($0.15).

Revenue of $13,287,000 higher by 54.79% from the same period last year, which missed the estimate of $14,940,000.


Immunogen hasn't issued any earnings guidance for the time being.

Immunogen hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: May 01, 2020

Time: 12:00 PM ET

Webcast URL:

Recent Stock Performance

Company's 52-week high was at $7.07

Company's 52-week low was at $1.76

Price action over last quarter: down 30.78%

Company Overview

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have licensed limited rights to use the ADC technology in their therapies.


Related Articles (IMGN)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at